High FSH and premature ovarian insufficiency
Menopause reversal treatment in Ireland
Medically reviewed by Dr. Phil Boyle, MICGP, MRCGP · Last reviewed May 2026
Premature ovarian insufficiency, or elevated FSH, is a condition where ovarian function declines earlier than expected. At NeoFertility, we assess whether follicular activity remains and apply targeted hormonal support to restore ovulation. It is not the right approach for every woman, but for those with residual function it is worth a clinical assessment.
At NeoFertility, we treat high FSH and premature ovarian insufficiency differently. We use a protocol designed to re-sensitise the ovarian follicle receptors that years of elevated FSH have gradually switched off.
It is not the right approach for every woman. But for those who still have residual follicular activity, it is worth a serious clinical assessment.
When FSH rises well above 30, IVF clinics typically advise against retrieval with your own eggs. That reflects what IVF is built around: collecting several eggs in a single stimulated cycle. It does not settle the separate question of what your own follicles can still do with the right support.
A restorative approach works with one good follicle at a time. And that changes what is possible.
How high FSH develops: the decline sequence
Ovarian reserve declines in a sequence, and the sequence matters clinically.
AMH falls first. It is the earliest marker of a reducing follicle pool. FSH rises later, as the pituitary works progressively harder to drive an ovary that is becoming less responsive.
By the time FSH is elevated, AMH is typically already very low. The two markers tell the same story from different angles, but they do not move together at the same time.
What matters clinically is what is happening at the follicle level. The primordial follicles carry FSH receptors on their surface.
When FSH is chronically elevated, those receptors are over-stimulated and gradually withdraw from the cell surface. They stop responding to signals from the pituitary.
The ovary appears unresponsive, not because all follicles are gone, but because the signalling system has shut down. That is the mechanism the restorative protocol targets.
The restorative approach to high FSH
So what we do is suppress the pituitary's own FSH, give the receptors time to recover, then stimulate.
The protocol Dr. Boyle uses is his adaptation of Jerome Check's 1984 and 1990 clinical work. The principle is to suppress your body's own FSH using continuous transdermal oestradiol at an HRT-type dose.
When FSH is held below a critical level, the receptors have time to return to the cell surface. That suppression period typically takes three to four months.
Follicular stimulation is then introduced in a planned sequence.
The critical detail is the FSH floor. This protocol is only appropriate when FSH is at least 25 to 30. Below that level, adding transdermal oestrogen suppresses ovarian function on its own rather than helping it recover.
In other words, this is not a protocol for women with moderately low AMH and normal FSH. That is a different clinical situation, covered on the Low AMH page.
Transdermal oestrogen is preferred over oral because oral preparations are processed by the liver first, which makes them more likely to cause clotting.
At HRT-type doses, transdermal oestradiol paired with appropriate progesterone support carries minimal risk in Dr. Boyle's clinical practice. The route matters in this specific context.
In Check's 1990 case series, 100 women with POI were treated using the transdermal-oestrogen FSH-suppression protocol. Of those, 19 conceived and 8 had live births.
This included women with very high FSH and long periods of absent menstruation. These figures come from Check's clinical practice and are cited by Dr. Boyle as the reference point for the approach.
They represent clinical case-series data, not a randomised trial. These are presented in that context, not as general population success rates.
Clinical cases: menopause reversal in practice
The cases we have seen confirm this protocol is worth offering carefully and honestly.
A 35-year-old woman with premature ovarian failure at FSH 23.7 came to us after five failed Clomid cycles, four intrauterine inseminations, and two IVF cycles without success.
With a restorative protocol that included low dose naltrexone, clomiphene, and HCG, she delivered a healthy boy on 26 March 2009 weighing 8 lb 7.5 oz. This is a clinic presentation case. It is one person. But it is a real person.
In a separate case presentation, a woman with AMH of 0.07 pmol/l and FSH of 45 IU/l on a day-9 reading had been advised to pursue IVF with donor eggs. NeoFertility's assessment found she still had follicular activity.
She conceived on the first cycle of letrozole ovulation induction with HCG trigger, in the second cycle of charting. She delivered a full-term male infant weighing 9 lb 0 oz by vaginal forceps delivery with no complications.
Again: one case. Not a rate. Not a prediction for your situation. But a reason to have the assessment rather than accepting the donor-egg recommendation without first asking whether the conversation is truly over.
"There's percentages and then there's people" is how Dr. Boyle frames this. The data here is thin, because this population is difficult to recruit for trials.
What exists is clinical experience, case reports, and a protocol grounded in a credible physiological mechanism. That is the honest picture, and we give it to you as it is.
Premature ovarian insufficiency: a distinct presentation
Premature ovarian insufficiency, or POI, is the clinical term for reduced or absent ovarian function before age 40.
The older term "premature menopause" is less accurate because POI is not always complete or permanent. Some women with POI have periods of intermittent spontaneous ovulation.
The FSH-suppression protocol is particularly relevant in this group. There may be residual follicular tissue that has not yet used up its potential. Whether it can be re-engaged depends on factors that only an assessment can answer.
POI may be linked to autoimmune conditions, chromosomal factors, prior chemotherapy or radiotherapy, or may have no identifiable cause.
Where autoimmune thyroid disease or other immune problems are present, NeoFertility investigates and treats that in parallel. The hormonal and immune workup in POI overlaps significantly with the standard hormonal dysfunction assessment.
Who this treatment is for
In Dr. Boyle's clinical experience, this protocol suits a specific group.
The protocol is most meaningful when FSH is at least 25 to 30 and some residual follicular activity can still be detected or suspected. He finds it most worthwhile up to the early forties, and does not generally pursue it past age 45.
These are not hard exclusions. They are the starting point for an honest conversation about what the evidence supports and what your specific situation looks like.
What the restorative approach will not do is promise an outcome. We are not in charge of whether conception follows. What we are in charge of is the quality of the investigation and the precision of the treatment.
If the follicle pool is present, we will find it. If it is recoverable, we will give it the best possible support. And if two to three cycles produce no follicular response, we will review the picture honestly together.
Starting menopause reversal treatment
The first appointment is a 45-minute consultation with Dr. Phil Boyle or Dr. Agnes Toth.
No GP referral is needed. Bring any recent blood results you have: FSH, AMH, LH, oestradiol. If you have had follicle-tracking scans or antral follicle count measurements, bring those too. If you have not yet done these tests, we can arrange them.
Start charting with ChartNeo as soon as possible. Even in high-FSH cases, the chart sometimes reveals follicular activity that blood tests alone miss.
A single IVF cycle in Ireland typically costs EUR 5,000 to EUR 8,000, and IVF with donor eggs is a further commitment on top of that.
The NeoFertility treatment plan covers up to 12 balanced cycles: consultations, blood tests, follicle-tracking scans, and pregnancy support. It is a fraction of that cost. See our pricing page for the full breakdown.
If you want to read about the stage just before this, where AMH is low but FSH has not yet risen to menopausal levels, our Low AMH page covers that ground.
And if recurrent miscarriage has been part of your picture alongside declining reserve, see our recurrent miscarriage page for how we approach that combination.
When you are ready, book your first consultation. If you are not sure yet, read more. Talk to couples who have been through it. And when the moment feels right, we are here.
Frequently asked questions
What does 'menopause reversal' mean in clinical practice?
The term is Dr. Boyle's framing for a specific protocol. Transdermal oestradiol is used to suppress high FSH and re-sensitise the FSH receptors on the follicles that remain in the ovaries.
When FSH stays chronically high, those receptors withdraw from the cell surface and stop responding to signals from the pituitary. By temporarily suppressing FSH with oestrogen, those receptors have time to return and become responsive again.
This is not restoring the ovaries to age 25. It is an attempt to re-engage the follicle pool that is still present. Whether conception follows depends on how much follicular activity can be recovered, and that varies between women.
Is this different from low AMH treatment?
It is, and it is worth understanding why. AMH is the first marker to fall as ovarian reserve declines. FSH rises later.
If your AMH is low but your FSH is still below 25, you are in the territory covered on the Low AMH page.
The approach there focuses on getting the best from the single follicle your ovary is still producing. The menopause reversal protocol applies when FSH has risen to at least 25 to 30, because that is the threshold above which the receptor problem becomes clinically relevant.
Below that level, adding transdermal oestrogen suppresses the ovaries on their own rather than helping them recover. The two protocols are related but distinct.
What is premature ovarian insufficiency (POI), and is it different from menopause?
Premature ovarian insufficiency, or POI, that is a mouthful, but it simply means the ovaries have reduced or stopped functioning before age 40. It is sometimes called premature menopause, though POI is not always permanent.
Some women with POI have periods of intermittent ovarian activity. That is exactly what the restorative approach tries to support. Natural menopause typically occurs around age 51. POI can occur from the twenties onwards.
In either case, if FSH has risen above 25 to 30 and follicular activity has become erratic or absent, the FSH-suppression protocol is the relevant treatment path.
Who is a candidate for this treatment?
In Dr. Boyle's clinical experience, the protocol is most useful when FSH is at least 25 to 30 and some residual follicular activity can still be identified.
He finds the protocol most worthwhile up to the early forties, and does not generally pursue it past age 45. These are not absolute exclusions. They are starting points for an honest conversation about what is realistic for you.
The assessment itself will tell us more than the numbers on a lab result alone.
How does the transdermal oestradiol protocol work?
The approach, adapted by Dr. Boyle from Jerome Check's 1984 and 1990 protocols, uses continuous transdermal oestradiol at an HRT-type dose to suppress your body's own FSH.
That suppression gives the FSH receptors on the follicles time to return to the cell surface. Primordial follicles take three to four months to respond once FSH is brought down. After that window, follicular stimulation is introduced in a planned sequence.
Transdermal oestrogen is preferred over oral because oral preparations are processed by the liver first, which makes them more likely to cause clotting. Transdermal oestradiol at this dose, paired with appropriate progesterone support, carries minimal risk in clinical practice.
What do the published results show?
The results here come from case reports and clinic presentations rather than large randomised trials, and we are honest about that.
In Jerome Check's 1990 case series, 100 women with POI were treated with the FSH-suppression protocol. Of those, 19 conceived and 8 had live births. This included women with very high FSH and long periods of absent menstruation.
In Dr. Boyle's own clinical case series, a 35-year-old woman with premature ovarian failure at FSH 23.7, after five failed Clomid cycles, four IUIs, and two IVF cycles, delivered a healthy boy on 26 March 2009 weighing 8 lb 7.5 oz.
In a separate clinic case, a woman with AMH of 0.07 pmol/l and FSH of 45 IU/l on a day-9 reading, advised donor eggs and IVF, conceived on the first letrozole cycle in the second cycle of charting.
She delivered a full-term boy weighing 9 lb 0 oz by vaginal forceps delivery.
These are individual cases, not population statistics. They are not a guarantee. They are a reason to have the assessment and the conversation.
Will I need to stop all my current hormonal support during this treatment?
That depends on what you are currently taking and why. The FSH-suppression protocol uses transdermal oestradiol as its main mechanism, so it interacts with any existing hormonal treatment.
Bear in mind that the goal is to temporarily suppress FSH below a threshold where follicular stimulation becomes meaningful again, then to reintroduce stimulation in a planned sequence.
We do not add oestrogen on top of an existing treatment plan without reviewing the full clinical picture first. This is a decision we make case by case at consultation.
What if the protocol does not restore ovulation?
We are honest about this from the first consultation. Not every case will respond. The follicle pool may be too small, or the ovarian tissue may not recover FSH receptor sensitivity in a useful timeframe.
If two to three cycles of the protocol produce no follicular activity on scan, we review the picture together and discuss what realistic options remain.
The restorative approach does not promise an outcome. It offers the most thorough investigation and the best-supported treatment for the follicular activity that remains. And at a fraction of the cost of repeated IVF cycles that were not designed for this situation.